In everyday clinical practice, we must follow only validated and standardized biomarkers with well-defined cut-off levels for use in the diagnosis, treatment strategy, and monitoring of asthma patients (AEC or eosinophil count in the sputum, FeNO and allergological examination, including skin prick testing and assessment of total and specific IgE). The gene discussed is IGHE; the disease is asthma.